Topic: infectious disease
Quest Diagnostics has launched three new test kits for STDs that consumers can order online, within the privacy of their own home.
By studying Ebola survivors' immune responses, scientists have gained new insights that could improve vaccine development.
Precision Bio files $100 million IPO for its off-the-shelf CAR-Ts after raising $110 million in a series B and signing a hep B alliance with Gilead.
Aradigm’s bid to get an inhaled antibiotic to market seems at an end, with its assets up for sale and the jobs of two primary executives terminated.
Motif Bio’s hope of adding to the antibiotic armamentarium for serious bacterial infections has just been dealt a blow by the FDA.
The first data readout from a phase 3 trial of Scynexis’ ibrexafungerp has come in and looks very positive for the first-in-class antifungal.
Day Zero Diagnostics raised $8.6 million in series A to rapidly profile the antibiotic resistance of infectious diseases using genomic sequencing.
U.K. biotech hVIVO is on course to start a phase 3 program for a flu vaccine that doesn’t need to have its composition tweaked every year.
Brii Biosciences is expanding on existing partnerships and inking a new deal with VBI Vaccines that could be worth up to $128.5 million.
The pact tasks Weissmann’s UPenn lab with taking vaccines against up to 10 infectious diseases through to the completion of IND-enabling studies.